Degron Therapeutics
Aims to become a global leader in the discovery and development of molecular glue degraders
San Diego, United States
25 employees
Series A
Total: $82.00M
Biotechnology, Health Care
General Information
Get notified when Degron Therapeutics moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Degron Therapeutics
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
United States Market
Biotechnology
About Degron Therapeutics
Taxonomy: biotech, drug discovery, molecular glue degraders, small molecule inhibitors, targeted protein degradation, therapeutics, scientific excellence, oncology, inflammation, metabolic diseases, medical innovation, pharmaceutical research, disease targets, global leader, unmet medical needs
Funding Rounds & Investors (6)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | •••••• | 8 |
|
01 May 2026 |
| Series A | •••••• | 1 | •••• •••• | 01 Dec 2025 |
| Series A | •••••• | 6 |
|
01 Dec 2024 |
| Grant | •••••• | 1 |
|
01 Dec 2023 |
| Series A | •••••• | 6 |
|
01 Jun 2022 |
Degron Therapeutics Alternatives & Competitors
Pioneering the future of cancer treatment with innovative small molecule therapeutics that enhance a...
NiKang Therapeutics, Inc. is a privately-held biotech company focused on developing novel small mole...
FAQ About Degron Therapeutics
Don't just browse. Track.
Signal Tracker monitors Degron Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.